

In the Claims

Claim 1 (Currently amended): A method for treating a sensory, motor and/or cognitive deficit wherein said method comprises the intracerebral administration of a ~~haematopoietic stem cell~~ hematopoietic stem cells to a patient in need of such treatment.

Claim 2 (Currently amended): The method, according to claim 1, which comprises intracerebral transplantation of said ~~stem cell~~ hematopoietic stem cells into a damaged brain.

Claim 3 (Previously amended): The method, according to claim 1, wherein the treatment is for a condition selected from the group consisting of Alzheimer's disease, Parkinson's disease, Korsakoff's disease and Creutzfeld-Jacob disease.

Claim 4 (Currently amended): The method, according to claim 1, wherein said ~~haematopoietic stem cell~~ hematopoietic stem cells are conditionally immortal.

Claim 5 (Currently amended): The method, according to claim 4, wherein said cell ~~comprises~~ hematopoietic stem cells comprise a temperature sensitive oncogene which is not expressed at a temperature above ~~35 °C~~ 35 °C.

Claim 6 (Previously amended): The method, according to claim 5, wherein said onocogene expresses the SV40 T- antigen.

Claims 7-9 (Cancelled)

Claim 10 (Currently amended): A pharmaceutical composition for treating a sensory, motor and/or cognitive deficit, wherein said composition comprises a ~~haematopoietic stem cell~~ hematopoietic stem cells and a pharmaceutically acceptable carrier.

Claim 11 (Currently amended): The composition, according to claim 10, wherein said ~~haematopoietic stem cell is~~ hematopoietic stem cells are conditionally immortal.

Claim 12 (Currently amended): The composition, according to claim 11, wherein the cell comprises hematopoietic stem cells comprise a temperature sensitive oncogene which is not expressed at a temperature above 35°C.

Claim 13 (Previously added): The composition, according to claim 12, wherein the oncogene expresses SV40 T-antigen.

Claim 14 (Cancelled)

**BEST AVAILABLE COPY**